DJT, BGFV and REAL Are Among After Hour Movers
Seeking AlphaApr 15 17:21 ET
Biomea Fusion Is Maintained at Outperform by Oppenheimer
Biomea Fusion Is Maintained at Outperform by Oppenheimer
Dow JonesApr 3 10:11 ET
Express News | Oppenheimer Maintains Outperform on Biomea Fusion, Maintains $70 Price Target
Moomoo 24/7Apr 3 10:01 ET
Biomea Fusion Drops as JPMorgan Downgrades on Data for Lead Asset
Seeking AlphaApr 2 13:18 ET
Express News | Biomea Fusion Shares Are Trading Lower After JP Morgan Downgraded the Stock From Overweight to Neutral and Lowered Its Price Target From $51 to $14
Moomoo 24/7Apr 2 10:54 ET
Biomea Fusion Cut to Neutral From Overweight by JP Morgan
Biomea Fusion Cut to Neutral From Overweight by JP Morgan
Dow JonesApr 2 10:32 ET
Express News | JP Morgan Downgrades Biomea Fusion to Neutral, Lowers Price Target to $14
Moomoo 24/7Apr 2 10:22 ET
Biomea Fusion Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 3.74% JP Morgan $51 → $14 Downgrades Overweight → Neutral 04/01/2024 270.51% HC Wainwright & Co
BenzingaApr 2 10:20 ET
Biomea Fusion (BMEA) Receives a Buy From Scotiabank
TipRanksApr 2 07:15 ET
Analysts Offer Insights on Healthcare Companies: Humana (HUM), Baxter International (BAX) and Biomea Fusion (BMEA)
TipRanksApr 2 03:50 ET
Promising Efficacy of Biomea Fusion's BMF-219 in Type 1 Diabetes Treatment: A Positive Outlook on Early Clinical Data
TipRanksApr 1 20:45 ET
Biomea Fusion, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and devel
GlobeNewswireApr 1 16:10 ET
Buy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Results and Strong Financial Position
TipRanksApr 1 12:05 ET
Express News | Truist Securities Reiterates Buy on Biomea Fusion, Maintains $55 Price Target
Moomoo 24/7Apr 1 10:25 ET
Biomea Fusion GAAP EPS of -$0.98
Seeking AlphaApr 1 10:06 ET
Express News | Biomea Fusion Q4 EPS $(0.98) Misses $(0.85) Estimate
Moomoo 24/7Apr 1 10:04 ET
Recap: Biomea Fusion Q4 Earnings
Biomea Fusion (NASDAQ:BMEA) reported its Q4 earnings results on Monday, April 1, 2024 at 09:00 AM.Here's what investors need to know about the announcement.EarningsBiomea Fusion missed estimated earni
BenzingaApr 1 09:50 ET
Biomea Fusion Highlights Initial Data From The First Two Type 1 Diabetes Patients Dosed With BMF-219
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesThe first two type 1 diabetes patients enrolled in COVALE
BenzingaApr 1 09:04 ET
Biomea Fusion 4Q Loss/Shr 98c >BMEA
Biomea Fusion 4Q Loss/Shr 98c >BMEA
Dow JonesApr 1 09:01 ET
Biomea Fusion 4Q Research and Development Expenses $30.9M >BMEA
Biomea Fusion 4Q Research and Development Expenses $30.9M >BMEA
Dow JonesApr 1 09:01 ET
No Data
No Data